Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV8-hCocH for Cocaine Use Disorder
NCT04884594Phase 1Active, not recruiting
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of AAV8-hCocH in cocaine use disorder (CUD) (3 arms). Primary endpoints: Adverse Events at 60 months and Change in enzyme expression profile at 24 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
AAV8-hCocH
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT04884594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884594.